Abstract
Background: Conventional therapeutic strategies for tumors have had limited success, and innovative and more effective approaches to treatment are urgently required. The ancient idea that various biological, bacterial, yeast, viral, and parasitic agents can be used as cancer therapeutics has gradually attracted considerable interest. Certain parasites have been widely discussed in association with human and animal tumors. The purpose of this review was to examine previous literatures which investigates the relations between Trichinella spiralis (T. spiralis) and tumors.
Methods: Using PubMed, articles published before 2018 in the whole world have been searched and comprehensively reviewed.
Results: Many researches have provided proofs that T. spiralis possesses antitumor activities. The antitumor effect of T. spiralis was first described in the 1970s. However, its research has been inconsistent, and little progress has been made in this field. Therefore, the mechanisms underlying these inhibitory effects are still unclear, and convincing evidence of the links between T. spiralis and the prevention or treatment of tumors from clinical trials is absent. Meanwhile, some other researches also suggested that T. spiralis may cause or contribute to coinfection with a tumors.
Conclusion: The review has highlighted the scientific literature focussing on evidence for T. spiralis to act as a pro- or antitumorigenic agent is summarized and discussed, in hope of contributing to a better understanding of the relations between T. spiralis and tumors.
Keywords: Trichinella spiralis, tumors, antitumor, tumorigenic, nurse cells, parasite.
Anti-Cancer Agents in Medicinal Chemistry
Title:Trichinella spiralis and Tumors: Cause, Coincidence or Treatment?
Volume: 18 Issue: 8
Author(s): Chengshui Liao*, Xiangchao Cheng, Mingyuan Liu*, Xuelin Wang and Pascal Boireau
Affiliation:
- Key Laboratory for Zoonosis Research, Ministry of Education, Institute of Zoonosis, Jilin University, Changchun,China
- Key Laboratory for Zoonosis Research, Ministry of Education, Institute of Zoonosis, Jilin University, Changchun,China
Keywords: Trichinella spiralis, tumors, antitumor, tumorigenic, nurse cells, parasite.
Abstract: Background: Conventional therapeutic strategies for tumors have had limited success, and innovative and more effective approaches to treatment are urgently required. The ancient idea that various biological, bacterial, yeast, viral, and parasitic agents can be used as cancer therapeutics has gradually attracted considerable interest. Certain parasites have been widely discussed in association with human and animal tumors. The purpose of this review was to examine previous literatures which investigates the relations between Trichinella spiralis (T. spiralis) and tumors.
Methods: Using PubMed, articles published before 2018 in the whole world have been searched and comprehensively reviewed.
Results: Many researches have provided proofs that T. spiralis possesses antitumor activities. The antitumor effect of T. spiralis was first described in the 1970s. However, its research has been inconsistent, and little progress has been made in this field. Therefore, the mechanisms underlying these inhibitory effects are still unclear, and convincing evidence of the links between T. spiralis and the prevention or treatment of tumors from clinical trials is absent. Meanwhile, some other researches also suggested that T. spiralis may cause or contribute to coinfection with a tumors.
Conclusion: The review has highlighted the scientific literature focussing on evidence for T. spiralis to act as a pro- or antitumorigenic agent is summarized and discussed, in hope of contributing to a better understanding of the relations between T. spiralis and tumors.
Export Options
About this article
Cite this article as:
Liao Chengshui *, Cheng Xiangchao, Liu Mingyuan *, Wang Xuelin and Boireau Pascal , Trichinella spiralis and Tumors: Cause, Coincidence or Treatment?, Anti-Cancer Agents in Medicinal Chemistry 2018; 18 (8) . https://dx.doi.org/10.2174/1871520617666171121115847
DOI https://dx.doi.org/10.2174/1871520617666171121115847 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
E2F1 and NF-κB: Key Mediators of Inflammation-associated Cancers and Potential Therapeutic Targets
Current Cancer Drug Targets Pharmacogenomics of Non-Small Cell Lung Cancer
Current Pharmacogenomics Inhalable Polymeric Micro and Nano-immunoadjuvants for Developing Therapeutic Vaccines in the Treatment of Non-small Cell Lung Cancer
Current Pharmaceutical Design The Epidemiology and Health Effects of Tobacco Use
Current Pediatric Reviews Feasibility of FDG PET in Inflammatory Bowel Disease
Current Molecular Imaging (Discontinued) Clinical Approaches to Immunotherapy in Non-Small Cell Lung Cancer: Current and Future Perspectives
Current Molecular Pharmacology Investigations of Malignant Mesothelioma
Current Respiratory Medicine Reviews Novel Approaches for Modulating dUTPase and Uracil-DNA Glycosylase: Potential Uses for Cancer and Viral Chemotherapy
Drug Design Reviews - Online (Discontinued) Ca<sup>2+</sup> Signalling in Endothelial Progenitor Cells: A Novel Means to Improve Cell-Based Therapy and Impair Tumour Vascularisation
Current Vascular Pharmacology COX-2 Selective Inhibitors, Carbonic Anhydrase Inhibition and Anticancer Properties of Sulfonamides Belonging to This Class of Pharmacological Agents
Mini-Reviews in Medicinal Chemistry The Mouse In Cancer Research Past, Present, Future
Current Genomics Phosphatidylinositol 3-kinase Signaling as a Therapeutic Target for Cervical Cancer
Current Cancer Drug Targets Novel Therapeutic Approaches in Limiting Oxidative Stress and Inflammation
Current Pharmaceutical Biotechnology Reducing the Burden of Cervical Cancer in the Developing World
Current Women`s Health Reviews Identification of Molecular Targets Associated with Ethanol Toxicity and Implications in Drug Development
Current Pharmaceutical Design Flavonoids Acting on DNA Topoisomerases: Recent Advances and Future Perspectives in Cancer Therapy
Current Medicinal Chemistry Cell Cycle and Cancer: The G1 Restriction Point and the G1 / S Transition
Current Genomics Current Perspectives on Novel Drug Delivery Systems and Therapies for Management of Prostate Cancer: An Inclusive Review
Current Drug Targets miRNA 21: Diagnostic Prognostic and Therapeutic Marker for Oral Cancer
MicroRNA Chemosensitization and Immunosensitization of Resistant Cancer Cells to Apoptosis and Inhibition of Metastasis by the Specific NF-κB Inhibitor DHMEQ
Current Pharmaceutical Design